Clonal architecture determination

PreclinicalBiologic

Clonal architecture determination is one of 46 biologic programs targeting Myelofibrosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelofibrosisActive, not recruiting

MyelofibrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Myelofibrosis

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

55 2

Ojjaara

GGlaxo Dba Glaxosmithkline

Approved

8 3

Rifadin

Tepadina

Droxia

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Vonjo

4 8

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

3 9

Navitoclax

AbbVie

Phase 3

5 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

N/ARecruiting

Myelofibrosis

NCT05710211

Clinical

Trials by Indication[1]

Myelofibrosis1 trial

Clonal Architecture of ASXL1-mutated Myelofibrosis

Recruiting·UUniversity Hospital, Angers·N/A·NCT05710211·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Clonal architecture determination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clonal architecture determination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clonal architecture determination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Angers company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Angers

Clonal architecture determination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Myelofibrosis1 trial

References

Drug Info

Quick Facts

Related News